Montipar-L Tablet is a combination medication containing levocetirizine (5mg) and montelukast (10mg) indicated for the relief of symptoms associated with allergic rhinitis and/or asthma. The levocetirizine component exerts its antihistaminic effects by selectively antagonizing the histamine H1 receptor, while the montelukast component inhibits the leukotriene D4 receptor, thereby blocking the cysteinyl leukotriene-mediated bronchoconstriction. This dual-action mechanism provides rapid and effective relief from symptoms such as nasal congestion, sneezing, runny nose, itchy and watery eyes, and wheezing. In patients with asthma, Montipar-L Tablet has been shown to improve lung function and reduce the frequency and severity of asthma exacerbations. The recommended dose is one tablet once daily, which can be taken with or without food. Montipar-L Tablet is contraindicated in patients with known hypersensitivity to any of its components, as well as in those with severe kidney or liver impairment. As with all medications, patients should be monitored for potential adverse effects and dosage adjustments made as necessary.